Tenof

Packaging Size : 30 Tablets

Dose/Strength 300 mg
Compare
Category:

Description

Tenof 300 mg is an antiviral medication indicated along with other anti-retroviral agents for HIV-1 infection in adults and children over 2 years of age. Additionally, it is used in hepatitis B viral (HBV) infection in similar population groups. Tenof 300 mg (Tenofovir disoproxil fumarate) acts by hindering the multiplication (replication) of the virus in human cells.

Tenofovir disoproxil fumarate is not used to cure HIV-1 infection but only to cut the HIV tool on the body. This allows to prevent some problems associated with HIV-1 infection and improve the life span.

Tenof tablet is administered orally in patients (adults and children over 2 years of age) weighing at least 35 kgs. For both HIV-1 and HBV infections, the dosage of 300 mg tablet remains the same.

Important measures while taking Tenof 300 mg:

  • The drug should be used once daily and at the same time everyday
  • It can be taken with or without food (best consumed with food)
  • At any cost, do not miss the dose as it lowers the amount of medicine in the blood leading to decreased effectiveness and increased
  • chances of the virus becoming resistant to (tenofovir disoproxil fumarate)

Recommended dosage of Tenof 300 mg in patients with kidney problems:

Testing Values (mL/min) Recommended dose (300 mg)
CrCl 50 or greater Every 24 hours
CrCl 30−49 Every 48 hours
CrCl 10−29 Every 72 to 96 hours
Hemodialysis Every 7 days or after completing the dialysis cycle

Note: Creatinine clearance test (CrCl): Used for checking the functioning of the kidney

Precautions and warnings associated with (Tenofovir disoproxil fumarate):

Initial testing before administering the drug:

HIV testing: It is important to test all HBV infected patients with HIV antibody testing before initiating tenofovir disoproxil fumarate.

Other warnings:

Tenof 300 mgNewly developed or worsening conditions of the kidney: The conditions may include acute renal failure (kidney failure) and Fanconi syndrome (excessive amounts of biomolecules e.g. glucose excreted via urine). Avoid the usage of tenofovir disoproxil fumarate if such patients are taking nephrotoxic drugs.

Inapparent changes in the immune system (immune reconstitution syndrome): This might occur in HIV-1 infected patients once they consume other HIV medications.

Problems in the bones: It can happen in children and sometimes in adults with symptoms like bone pain, softening of bones, or thin bones. These events may lead to fractures in some scenarios so, bones should be checked regularly.

Excessive amount of lactic acid in the blood (lactic acidosis): It is a rare medical emergency with the occurrence of symptoms like unusual weakness and pain in the muscles, slow or fast breathing, stomach pain with vomiting/nausea, cold hands and feet, dizziness, or abnormal heartbeats. If such symptoms are seen, the respective doctor should be immediately consulted.

Severe complications in the liver: Even though it is rare, it may lead to the death of patients. Look for symptoms like yellow-colored eyes, dark colored urine, loss of appetite, nausea, or pain in the abdomen, if found immediately refer to the respective doctor.

Side-effects of Tenof 300 mg tablet:

Tenofovir disoproxil fumarate has a reasonable safety profile with a low occurrence of side-effects. In both HIV-infected adults and children, side-effects were,

  • Rashes on skin
  • Diarrhea
  • Nausea
  • Depression
  • Weakness

however, in HBV patients the occurrence of side-effects was dependant on the type of HBV infection.

Side-effects in HBV patients:

HBV-infected patients with compensated liver disease HBV-infected patients with decompensated liver disease
Nausea Abdominal pain and itching
Nausea and fever
Difficulty in sleeping
Vomiting and dizziness

Note: These are not all side-effects of Tenof tablet. Consult your doctor for medical advice regarding the side-effects.

Brand

Hetero

Reviews

There are no reviews yet.

Be the first to review “Tenof”

Your email address will not be published. Required fields are marked *

×